Given the IL-1-mediated nature of these comorbidities, and the documented favorable effects of IL-1 blockade on cardiovascular and metabolic diseases (discussed above in the present review; Dinarello et al., 2012), benefits of anakinra in RA may extend beyond the mere efficacy on articular inflammation and are worth further exploration. The gene discussed is IL1A; the disease is Other metabolic disease.